In summary, the PI3K/AKT/mTOR pathway is a critical target in ovarian cancer therapy, and the combination of PI3K inhibitors with PARP inhibitors shows promise in some ovarian cancer patients. This evidence concerns the gene AKT1 and ovarian cancer.